Ketamine: Mechanisms and Relevance to Treatment of Depression.
Kim JW, Suzuki K, Kavalali ET, Monteggia LM.
Annu Rev Med. 2024 Jan 29;75:129-143. doi: 10.1146/annurev-med-051322-120608. Epub 2023 Sep 20.
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA Jr, Stahl S.
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
Bahji A, Vazquez GH, Zarate CA Jr.
J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23.
Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.
Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA.
Lancet Psychiatry. 2022 Nov;9(11):907-921. doi: 10.1016/S2215-0366(22)00317-0.
Personalized use of ketamine and esketamine for treatment-resistant depression.
Medeiros GC, Demo I, Goes FS, Zarate CA Jr, Gould TD.
Transl Psychiatry. 2024 Nov 29;14(1):481. doi: 10.1038/s41398-024-03180-8.
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB.
JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189.
Esketamine for treatment resistant depression.
Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA, Baker G, Dursun S, Klassen LJ, Chokka P, Demas ML.
Expert Rev Neurother. 2019 Oct;19(10):899-911. doi: 10.1080/14737175.2019.1640604. Epub 2019 Jul 16.
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, Gobbi G.
J Neurosci. 2021 Feb 3;41(5):891-900. doi: 10.1523/JNEUROSCI.1659-20.2020. Epub 2020 Nov 30.
Ketamine: A tale of two enantiomers.
Jelen LA, Young AH, Stone JM.
J Psychopharmacol. 2021 Feb;35(2):109-123. doi: 10.1177/0269881120959644. Epub 2020 Nov 6.
Ketamine in neuropsychiatric disorders: an update.
Johnston JN, Kadriu B, Kraus C, Henter ID, Zarate CA Jr.
Neuropsychopharmacology. 2024 Jan;49(1):23-40. doi: 10.1038/s41386-023-01632-1. Epub 2023 Jun 20.
